Expression and functionality of TRPV1 in breast cancer cells

Lea V Weber1
Klaudia Al-Refae1
Gerhard Wölk2
Gabriele Bonatz3
Janine Altmüller4
Christian Becker4
Günter Gisselmann1
Hanns Hatt1

1Department of Cell Physiology, Ruhr-University Bochum, Bochum, 2Herz-Jesu-Krankenhaus, Dernbach, 3Augusta Kliniken Bochum, Bochum, 4Cologne Center for Genomics, University of Cologne, Cologne, Germany

Abstract: Transient receptor potential (TRP) channels contribute to the regulation of intracellular calcium, which can promote cancer hallmarks in cases of dysregulation of gene transcription and calcium-dependent pro-proliferative or anti-apoptotic mechanisms. Several studies have begun to elucidate the roles of TRPV1, TRPV6, TRPM8, and TRPC1 in cancer progression; however, no study has examined the expression profiles of human TRP channels in breast cancer on a large scale. This study focused on the expression and functionality of TRPV1, a nonselective cation channel that was found to be expressed in different carcinoma tissues. Next-generation sequencing analyses revealed the expression of TRPV1 in several native breast cancer tissues, which was subsequently validated via reverse transcriptase-polymerase chain reaction. Activation of TRPV1 by its ligand capsaicin was associated with the growth inhibition of some cancer cell types; however, the signaling components involved are complex. In this study, stimulation by the TRPV1 agonist, capsaicin, of SUM149PT cells, a model system for the most aggressive breast cancer subtype, triple-negative breast cancer, led to intracellular calcium signals that were diminished by the specific TRPV1 antagonist, capsazepin. Activation of TRPV1 by capsaicin caused significant inhibition of cancer cell growth and induced apoptosis and necrosis. In conclusion, the current study revealed the expression profiles of human TRP channels in 60 different breast cancer tissues and cell lines and furthermore validated the antitumor activity of TRPV1 against SUM149PT breast cancer cells, indicating that activation of TRPV1 could be used as a therapeutic target, even in the most aggressive breast cancer types.

Keywords: TRP channels, TRPV1, next-generation sequencing, breast cancer, apoptosis, necrosis, anti-proliferative

Introduction
Breast cancer is one of the most common cancers affecting women worldwide.1 A series of high-throughput methods have changed cancer research and therapy.2–4 Expression profiling on a genomic scale led to the classification of the intrinsic subtypes of breast cancer, thus allowing for the prediction of disease progression and patient stratification.3 Treatment options are highly diverse; whereas human epidermal growth factor receptor 2 (HER2)-positive breast cancers can be targeted by specific drugs, the triple-negative breast cancer phenotype is defined by chromosomal instability and low expression levels of estrogen receptor (ER) alpha, progesterone receptor (PR), and HER2, rendering treatment rather difficult.5 Triple-negative breast cancer is characterized by limited treatment options and frequent local recurrence.6

Transient receptor potential (TRP) channels, which are membranous ion channels that conduct calcium and sodium ions, have been shown to influence cancer cell...
growth. These channels can be activated by many stimuli, including temperature or pH changes in the extracellular space. TRP channels play an important role in the development of several diseases, and one of the most investigated and described TRP channel is TRPV1. TRPV1 agonist, capsaicin, is capable of inducing apoptosis and inhibiting cancer cell growth by cell cycle arrest in many different types of cancer, for example, osteosarcoma, colon, and pancreatic cancer cells, while normal cells remained unharmed. A less-pungent capsaicin-like analog, RPF151, showed antitumor activity in a murine breast cancer model in vivo, demonstrating the possibility of managing the induction of pain.

In this study, we aimed, on the one hand, to elucidate the expression profiles of TRP channels in a large amount of breast cancer tissues via RNA-Seq. On the other hand, we analyzed the expression of TRPV1 in detail to contribute to the understanding of the influences of TRPV1 activation in novel breast cancer therapy.

Materials and methods

Tissue preparation and reverse transcriptase (RT)-polymerase chain reaction (PCR)

Breast cancer tissues were obtained from Dr Bonatz, Augusta-Krankenanstalt Bochum, and Dr Wölk, Herz-Jesu Klinik Dernbach. Each patient provided written consent and gave permission for the storage of their samples for the use in research and development purposes. Identities were entirely concealed in accordance with the Declaration of Helsinki. The tumor tissue samples were maintained in RNAlater. RNA was isolated from the tumor samples using a homogenizer (Precellys®; Bertin Corp., Rockville, MD, USA) with 1.4 ceramic beads (Precellys®) and with an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocols. cDNA synthesis was performed using the iScript™ cDNA Synthesis Kit according to the manufacturer’s protocol (Bio-Rad, Hercules, CA, USA). RT-PCR was conducted to validate the expression of the detected olfactory receptors. PCR was performed using GoTaq qPCR Master Mix. The PCR included the following steps: 3 min, 95°C, 40 cycles of 1 min at 60°C (TRPV1) and 1 min at 72°C. A Mastercycler® ep reaplex (Eppendorf, Hamburg, Germany) was used.

Primers are as follows:

TRPV1 – forward: CAGGGAAGACCTGTCTGCTG; reverse: ACAAGCTCCTTCAGGCTGTC.

Chemicals

Capsaicin was purchased from Sigma-Aldrich (St Louis, MO, USA). The inhibitor capsazepin and the TRP channel inhibitor ruthenium red were purchased from Abcam (Cambridge, MA, USA). Ringer’s solution contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 10 mM (4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid), at a pH of 7.4. The substances were prediluted in dimethyl sulfoxide (DMSO) prior to usage. The final concentration of DMSO solvent was maximally 0.1% for each experiment.

Next-generation sequencing

For standard mRNAseq (Illumina, San Diego, CA, USA), we used the TruSeq™ RNA Sample Prep Kit v2 protocol (Illumina). HiSeq 2000 (2 × 102 bp reads) was used for RNA-Seq. In total, 11 breast cancer tissue samples were analyzed in cooperation with the Cologne Center for Genomics (CCG). Raw data were generated for breast cancer samples in fastq format. Hg19 of the human genome and transcriptome was used to align the reads. The alignment was arranged by the Bowtie program included in TopHat (version 1.2.0). The output files were sorted and indexed by the SAMtools program in BAM format. The number of the aligned mRNA-Seq reads was calculated using the Cufflinks program, which uses the RefSeq hg19 reference transcriptome in Gene Transfer Format (GTF; obtained from the USCS Genome Bioinformatic database, University of California, Santa Cruz, CA, USA). The Cufflinks program was used for the quantification of the relative abundance of transcripts for each gene, using the unit FPKM (fragments per kilobase of exon per million fragments mapped). For visualization of the data sets and the analysis of the read distribution, the Integrative Genomic Viewer was used (www.broadinstitute.org/igv).

Cell culture

SUM149PT cells were purchased from Asterand Bioscience (Detroit, MI, USA). The cells were cultivated in Roswell Park Memorial Institute (RPMI) medium containing 10% fetal bovine serum, glutamine (5%) and 100 units/mL penicillin/streptomycin (Gibco®; Thermo Fisher Scientific, Waltham, MA, USA). Cultivation was performed in an incubator with a humidified atmosphere at 37°C in 10% CO2. SUM149PT cells were passaged every 3–4 days at a confluence of 85% using TrypLE™ (Thermo Fisher Scientific).

Calcium imaging

SUM149PT cells were incubated at 37°C for 30 min with Ringer’s solution containing 3 mM FURA-2-AM (fura-2-acetoxyethyl ester; Molecular Probes, Eugene, OR, USA). For calcium imaging experiments, the growth medium was replaced by extracellular medium. Fluorimetric imaging was performed according to the standard protocol by Spehr et al.
SUM149PT cells were exposed to capsaicin two to three times for 30–60 s, depending on the experimental approach. The concentrations ranged from 3–10 μM to 500 μM. The inhibitors ruthenium red and capsazepin were co-applied at concentrations of 5 and 10 μM. ATP (10 μM) served as a control and was applied after every measurement.

**Scratch assays**

Scratch assays were essentially performed as described in the study by Busse et al.23 For stimulation, Dulbecco’s Modified Eagle’s Medium containing capsaicin was used at concentrations of 150 and 200 μM. The software TScratch was used to calculate the overgrowing gap relative to the initial scratch area.24

**Proliferation assay**

SUM149PT cells were seeded at a density of 5 × 10³ cells in 96-well plates. After 24 h of cultivation, the cells were stimulated with RPMI + capsaicin (150 and 200 μM) and RPMI + 0.1% DMSO. The CyQuant® NF assay (Thermo Fisher Scientific) was used according to the manufacturer’s protocol. Excitation at 485/20 nm and fluorescence detection at 528/20 nm were measured to calculate fluorescence intensities.

**Annexin V-fluorescein isothiocyanate (FITC) staining**

The apoptosis assay was performed by staining the SUM149PT cells with FITC-labeled Annexin V and propidium iodide (PI), using the Annexin V-FITC Apoptosis Detection Kit (Abcam), according to the manufacturer’s instructions. In brief, SUM149PT cells were treated with capsaicin (10 and 150 μM) or control for 48 h. The cells were washed twice with phosphate-buffered saline (PBS) and were resuspended with the Annexin V binding buffer. Then, the cells were incubated with FITC-labeled Annexin V and PI for 15 min in the dark at room temperature. For detection, a fluorescence microscope (Axioskop; Zeiss, Oberkochen, Germany) was used.

**Caspase assay**

For the detection of apoptosis, the Caspase-3 Colorimetric Assay Kit by Abcam was used according to the manufacturer’s protocol. SUM149PT cells were seeded and incubated on 12 mm coverslips and placed in 24-well plates containing medium. The medium was replaced by medium containing capsaicin (150 μM) or DMSO for 14 h. Cells were fixed for 20 min with 4% paraformaldehyde (PFA) and were washed twice with 2 mL of PBS + Triton X-100 for 10 min. The cells were blocked for 60 min with blocking buffer (PBS, 10% fish gelatin, 0.5% goat serum) at room temperature. Primary antibody-detecting caspase-3 (diluted 1:300 in blocking solution) was incubated overnight at 4°C. Before incubation for 1 h with the secondary antibody (purchased from Cell Signaling) at 1:1000 dilution including 2 μL of 4’,6-diamidino-2-phenylindole, the cells were washed thrice with PBS + TritonX-100. The cells were fixed with ProLong® Gold Antifade. Analysis was performed with an LSM 510 Meta (Zeiss).

**Immunocytochemistry**

SUM149PT cells were grown on coverslips in 24-well cell culture plates. PFA at a concentration of 4% was used for fixation of the cells. After fixation, the cells were washed and permeabilized in PBS + 0.1% Triton X-100. The blocking reagent contained phosphate buffered saline tween-20 + 1% fish gelatin and was incubated for 1 h at room temperature. The TRPV1 antibody was incubated overnight at 4°C. Subsequently, the cells were washed three times, and the secondary antibody coupled to Alexa Fluar 488 (Thermo Fisher Scientific) was added for 45 min at room temperature. To analyze the images, a Zeiss LSM 510 Meta confocal microscope (Zeiss) was used.

**Statistics**

Every result was tested for normality (Shapiro–Wilk test) and equal variance. Normally distributed data were analyzed using Student’s two-tailed unpaired t-test. Data that were not normally distributed were analyzed by the Mann–Whitney U test. Every result contained at least three independent experiments so that the mean standard error of the mean is shown. Statistical significance was indicated as follows: *p<0.05, **p<0.01, ***p<0.001.

**Results**

**Expression of TRP channels in breast cancer**

Several studies have demonstrated the influence of some TRP channels on breast cancer cell progression.25–27 Therefore, we aimed to identify the expression patterns of 16 human TRP channels in native breast cancer tissues and cell lines, and we analyzed the transcriptome of 11 different breast cancer tissues via RNA-Seq (Figure 1). We investigated the tissue samples in cooperation with the CCG and generated at least five Mio reads for each sample, using paired-end sequencing analysis and reanalyzed the data sets from the NCBI archive. In this study, we could detect a broad range of TRP channels with high expression values (FPKM > 10) in different breast cancer tissues.
In addition, we reanalyzed the transcriptome data of 49 breast cancer cell lines originating from several different tumor types (Figure 2) with focus on the expression of TRP channels. In this study, we used the innovative classification of breast cancer subtypes, revealed by extensive genomic analyses of breast cancer tissues and based on the molecular profiles of the cells, for example, luminal A, luminal B, basal-like, triple-negative, or BRCA1 mutated.28,29 There were only two TRP channels expressed in every tissue sample, namely TRPM7 and TRPV1 (Figure 2). Because TRPM7 is known to be expressed in a large number of different cell types,30 it could not be considered a suitable, specific target for cancer therapy. In comparison, TRPV1 is not expressed in such a broad range; furthermore, it is associated with breast tumor growth inhibition.8,31,32 We showed the average expression level of TRP channels in breast cancer cell lines and the expression in healthy breast tissues, using data obtained from the Gtex database (www.gtexportal.org; Figure 2E). TRPV1 was overexpressed in breast cancer tissues compared to normal breast tissues. Some TRP channels were expressed in neither tumor tissues nor healthy tissues, for example, TRPC5 and TRPC7. TRPA1 was differentially expressed; there was no expression in healthy breast tissues but particular expression in some luminal breast tumors.

Another interesting TRP channel is TRPM8, which was not expressed in healthy breast tissues but was expressed in many breast cancer samples, regardless of the subgroup. An almost contrary effect could be observed for TRPV2, showing a high expression (FPKM > 6) in healthy breast tissues but low to almost no expression in the different breast cancer subtypes. Strikingly, the luminal breast cancer subtype showed the least expression, and in the majority of samples no expression existed at all.

Expression of TRPV1 in breast cancer cells

With an average FPKM value of 4.9, TRPV1 showed the highest expression in triple-negative breast cancer cells (Figure 3A). Therefore, we focused on the investigation of TRPV1 and validated the expression of TRPV1 in breast cancer tissue samples via RT-PCR (Figure 3).

We analyzed the function of TRPV1 in SUM149PT cells, which were developed from an invasive, inflammatory triple-negative ductal carcinoma, one of the most aggressive breast cancer types. Figure 4 shows the self-generated RNA-Seq data of SUM149PT cells, as well as the expression of TRPV1 at the mRNA and protein levels via RT-PCR and immuno-cytochemistry, using specific TRPV1-detecting antibodies (Figure 4B and C).
TRP channels in breast cancer

Figure 2  Heat map of TRP channel expression in 49 breast cancer cell lines and healthy tissues.

Notes: (A) Breast cancer cell lines derived from tumors with mutated BRCA1 genes; n = 3. (B) Breast cancer cell lines derived from basal-like breast tumors; n = 15. (C) Breast cancer cell lines derived from luminal breast tumors; n = 23. (D) Breast cancer cell lines derived from triple-negative breast tumors; n = 8. (E) Expression of the 16 TRP channels observed in healthy breast tissues (n = 214, data obtained from Gtex, www.gtexportal.org). FPKM values are visualized by different colors. The expression level correlates with the color depth.

Abbreviations: FPKM, fragments per kilobase of exon per million fragments mapped; TRP, transient receptor potential.
Characterization of TRPV1 in SUM149PT cells

To analyze the function of TRPV1 in SUM149PT cells, we investigated the effect of ligand (capsaicin) stimulation. We conducted calcium imaging experiments and could elicit calcium signals at the concentration of 100 µM capsaicin (Figure 5A and B), which were abolished by coapplication of the TRPV1 antagonist capsazepin (Figure 5F). In total, 10% of the cells could be activated by capsaicin at the concentration of 10 µM, and ~20% of the cells showed calcium signals upon stimulation with 100 µM capsaicin in calcium imaging experiments. Next, we investigated the physiological effects of capsaicin by migration and proliferation assays. Stimulation of SUM149PT cells with capsaicin (150 µM) for 48 h induced a significant reduction in cell proliferation (Figure 5C). Furthermore, we performed scratch assays, which are used to analyze cell migration. When stimulated with capsaicin (150 µM) for 48 h, the cells showed a reduced migration into the gap and altered their morphology, indicating cell transition into apoptosis (Figure 5D). Therefore, we performed immunocytochemical staining for the detection of apoptosis and necrosis, using the Annexin V-FITC Kit, which allowed for differentiation among early apoptotic cells, necrotic cells, and viable cells (Figure 5E). Stimulation with capsaicin (10 and 150 µM) induced apoptotic and necrotic cell death (Figure 5E). Approximately 37% of the cells became necrotic upon stimulation with capsaicin (150 µM). Then, we examined whether the capsaicin-induced effect on cell proliferation was mediated by TRPV1 using the TRPV1-specific antagonist capsazepin (50 µM). The reduction in cell proliferation was diminished by the coapplication of capsaicin (50 µM) and capsazepin (50 µM) in comparison to capsaicin alone (Figure 5G).

Figure 3 Expression of TRPV1 in breast cancer tissues and cell lines.
Notes: (A) Comparison of expression of TRPV1 in all breast cancer subtypes investigated. (B) Read coverage of TRPV1 detected in one of the breast cancer tissue samples and visualized by the Integrative Genomic Viewer. (C) Validation of TRPV1 expression in five breast cancer tissue samples via RT-PCR. +, +RT, cDNA; -, -RT, RNA; gDNA, genomic DNA as a control.
Abbreviations: BC, breast cancer; M, marker; PCR, polymerase chain reaction; RT, reverse transcriptase; TNBC, triple-negative breast cancer.
Figure 4 Expression profiles of TRP channels in the SUM149PT breast cancer cell line. Notes: (A) NGS-based RNA-Seq analysis of the expression of TRP channels. (B) Validation of the expression of TRPV1 in SUM149PT cells via RT-PCR. +, +RT, cDNA; -, -RT, RNA; g, genomic DNA as a control. (C) Immunocytochemical staining of SUM149PT cells with specific TRPV1 antibodies. Left: SUM149PT cells. Right: Negative control: SUM149PT cells stained with secondary antibody alone. Staining of the cell nuclei was performed using DAPI (blue). Scale bar: 10 µm. Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; M, marker; NGS, next-generation sequencing; PCR, polymerase chain reaction; RT, reverse transcriptase; TRP, transient receptor potential.

Discussion

In this study, we aimed to identify the expression profiles of TRP channels in different breast cancer subtypes and to investigate the effect of TRPV1 ligand on breast cancer progression. The targeting of different TRP channels in several cancer types has become increasingly important, because the roles of TRPs in tumorigenesis and cancer progression have been impressively proved by the detection of assigned oncogenic properties for most TRPs.10 In this study, the comprehensive RNA-Seq analysis of 11 breast cancer tissues and 49 breast cancer cell lines revealed a considerable amount of data. To our knowledge, no studies have yet conducted a large-scale comparative study of the TRP expression profiles in breast cancer cell lines. In this study, TRPM7 showed the highest expression. TRPM7 is known to regulate many features of malignant cancers; for example, it mediates cell migration and invasion through the MAPK pathway in MDA-MB-435 breast cancer cells.26,33 Because of the broad expression of TRPM7 also in healthy cells, it is an unsuitable target for tumor therapy. Other TRP channels showed differential expression; TRPA1 is not expressed in the healthy tissue but in some breast tumor tissues, especially in the luminal subtype. Analyzing the association between TRPA1 expression and the progression of luminal breast cancer will be the aim of future studies. TRPM8 was also expressed in breast cancer tissues only, regardless of the molecular subtype. This finding was in accordance with studies describing TRPM8 as a potential cancer biomarker and a therapeutic target in pancreatic cancer.34,35 Furthermore, we showed the opposite expression pattern for TRPV2, which was highly expressed in healthy breast tissues and weakly expressed in breast cancer tissues. Of course, these data are not sufficient to draw conclusions concerning TRP channels as novel biomarkers for breast cancer subtypes, but they could serve as the basis for further investigations. TRPV1, a nonselective cation channel, was the second most highly expressed TRP channel in our data set and was detectable in all...
Figure 5 Functional characterization of TRPV1 activation by capsaicin in SUM149PT cells.

Notes: (A) Representative image of SUM149PT cells stimulated with capsaicin (10 µM) in calcium imaging analysis. To ensure the viability of the cells, ATP (10 µM) was applied finally and served as a positive control. N > 3 with n = 12 measurements in six cell culture dishes with ~200 cells. (B) Activation of SUM149PT cells upon repetitive capsaicin application (10 µM). (C) Analysis of cell proliferation via CyQuant proliferation assay after capsaicin stimulation for 48 h (150 µM); n = 20. (D) Analyses of cell migration by scratch assay after capsaicin (150 µM) stimulation for 48 h. Bar chart showing statistical analysis of the area overgrown in scratch assay experiments; n = 3 assays. (E) Annexin V-FITC staining of SUM149PT cells stimulated by capsaicin (10 and 150 µM). Early apoptotic cells (Annexin V positive, PI negative) are shown in green; necrotic cells (Annexin V positive, PI positive) are shown in yellowish-red, and viable cells are shown in bright phase (Annexin V negative, PI negative). Bar chart showing statistical analysis of cells undergoing necrosis; n = 3 stains of five slices with ~300 cells. (F) Calcium signal upon application of capsaicin (100 µM) and capsaicin (100 µM) + capsazepin (50 µM); n = 6 cell culture dishes with ~200 cells. The shaded area represents the application of the antagonist capsazepin. (G) Analysis of the cell proliferation via CyQuant proliferation assay after capsaicin (50 µM) and capsaicin (50 µM) + capsazepin (50 µM) stimulation for 48 h; n = 10. *P<0.05, **P<0.001. Scale bar = 10 µm.

Abbreviations: C, capsaicin; CZ, capsazepin; FITC, fluorescein isothiocyanate; PI, propidium iodide; F340/F380, ratio of the fluorescence intensities at 340 nm and 380 nm excitation; C, capsaicin; CZ, capsazepin; ATP, adenosine triphosphate; ns, not significant.
samples. TRPV1 is known to be expressed in several different neoplastic tissues, such as squamous cell carcinoma of the tongue, hepatocellular carcinoma, or transitional carcinoma of the human bladder, and it has also been associated with growth and progression in breast cancer cells. In MCF-7 breast cancer cells, the mediation of cell death upon stimulation with the ligand capsaicin was demonstrated. In preliminary investigations, Vercelli et al demonstrated a reduction in cell proliferation upon application of the TRPV1 agonist capsaicin. Interestingly, even the inhibitor, capsazepin, showed the same effect. Actually, the investigation of TRPV1 as a novel target in breast cancer is far from complete, not least because its functionality differs in healthy breast cells and cancerous cells. Therefore, we aimed to investigate the effect of TRPV1 in a triple-negative breast cancer cell line. TRPV1 showed the highest average expression in this study, followed by luminal and basal-like breast cancer subtypes. SUM149PT displayed a triple-negative breast cancer phenotype, defined by the absence of ER, PR, and HER2. This cancer type accounts for 15%–20% of all breast cancer cases and shows poor prognosis with only a 40% 5-year survival rate due to the insensitivity to some of the most effective ligands. In prostate cancer cells, in which its activation by capsaicin signaling was demonstrated as well. 46 This induction led to the suggestion that activation of TRPV1 by specific ligands could significantly enhance breast cancer cell death, even in the most aggressive breast cancer subtype, triple-negative breast cancer. The mechanisms involved leading to apoptosis remain elusive.

**Conclusion**

We conducted a meta-study of the expression patterns of all human TRP channels in different breast cancer subtypes and showed that TRPM7 and TRPV1 were the only channels expressed in every sample. Furthermore, TRPV1 showed the highest average expression in triple-negative breast cancer subtypes. Analyzing channel activation, we demonstrated anti-proliferative, anti-migratory and apoptosis/necrosis-inducing effects of capsaicin treatment due to the activation of TRPV1 in SUM149PT cells, which is a model system for triple-negative inflammatory breast cancer, the most aggressive breast cancer subtype.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin*. 2014;64(4):252–271.
2. Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-generation sequencing in breast cancer: first take home messages. *Curr Opin Oncol*. 2012;24(6):597–604.
3. Garraway LA, Lander ES. Lessons from the cancer genome. *Cell*. 2013;153(1):17–37.
4. Karn T. High-throughput gene expression and mutation profiling: current methods and future perspectives. *Breast Care (Basel)*. 2013;8(6):401–406.
5. Opyrchal M, Salisbury J, Lankov I, et al. Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24− Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. *Int J Oncol*. 2014;45(3):1193–1199.
6. Navratil J, Fabian P, Palacova M, et al. Triple negative breast cancer. *Klin Onkol*. 2015;28(6):405–415.
7. Benemeri S, Palacini R, Trevisani M, Gepetto P. TRP channels. *Curr Opin Pharmacol*. 2015;22:18–23.
8. Bodding M. TRP proteins and cancer. *Cell Signal*. 2007;19(3):617–624.
9. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. *Ann Rev Physiol*. 2006;68:619–647.
28. Liu ZF, Chen C, Yao XL, et al. Clinicopathological characteristics and outcomes of glioma patients treated with TRPV1 blocking agents. *Semin Oncol Nurs.* 2015;31(2):108–121.

29. Berse B, Lynch JA. Molecular diagnostic testing in breast cancer. *Semin Oncol Nurs.* 2015;31(2):357–369.

30. Paravincini TM, Chubanov V, Gudermann T. TRPM7: a unique channel involved in magnesium homeostasis. *Int J Biochem Cell Biol.* 2012;44(8):1381–1384.

31. Lazzetti L, Vannucci MG, Spinelli M, et al. Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder. *Eur Urol.* 2005;48(4):691–699.

32. Bode AM, Cho Y, Zheng D, et al. The transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. *Cancer Res.* 2009;69(3):905–913.

33. Zhou W, Guo S, Xiong Z, Liu M. Oncogenic role and therapeutic target of transient receptor potential melanin 7 channel in malignancy. *Expert Opin Ther Targets.* 2014;18(10):1177–1196.

34. Yee NS. Roles of TRPM8 ion channels in cancer: proliferation, survival, and invasion. *Cancers (Basel).* 2015;7(4):2134–2146.

35. Yee NS. TRPM8 ion channels as potential cancer biomarker and target in pancreatic cancer. *Adv Protein Chem Struct Biol.* 2016;104:127–155.

36. Marincsak R, Toth BI, Czifra G, et al. Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. *Oral Dis.* 2009;15(5):328–335.

37. Miao X, Liu G, Xu X, et al. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet.* 2008;186(1):25–32.

38. Sharma SK, Vij AS, Sharma M. Mechanisms and clinical uses of capsaicin. *Eur J Pharmacol.* 2013;720(1–3):55–62.

39. Vercelli C, Barbero R, Cunicerti B, Odore R, Re G. Expression and functionality of TRPV1 receptor in human MCF-7 and canine CF-41 cells. *Vet Comp Oncol.* 2015;13(2):133–142.

40. Yang F, Zhang W, Shen Y, Guan X. Identification of dysregulated microRNAs in triple-negative breast cancer (review). *Int J Oncol.* 2015;46(3):927–932.

41. Park YR, Chun JN, So I, et al. Data-driven analysis of TRP channels in cancer: linking variation in gene expression to clinical significance. *Cancer Genomics Proteomics.* 2016;13(1):83–90.

42. Sanchez MG, Sanchez AM, Collado B, et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in lNCaP and PC-3 prostate cancer cells and in human prostate tissue. *Eur J Pharmacol.* 2005;515(1–3):20–27.

43. Vercelli C, Barbero R, Cunicerti B, et al. Transient receptor potential vanilloid 1 expression and functionality in mcf-7 cells: a preliminary investigation. *J Breast Cancer.* 2014;17(4):332–338.

44. Zheng L, Chen J, Ma Z, et al. Capsaicin enhances anti-proliferation efficacy of pirarubicin via activating TRPV1 and inhibiting PCNA nuclear translocation in 5637 cells. *Mol Med Rep.* 2015;12(1):881–887.

45. Dhirgra K, Frye D, Newman RA, et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. *Clin Cancer Res.* 1995;1(7):691–697.

46. Ziglioli F, Frattini A, Maestroni U, Dinale F, Ciuffieda M, Cortellini P. Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV1-dependent and a TRPV1-independent mechanism. *Acta Biomed.* 2009;80(1):13–20.

---

**Breast Cancer - Targets and Therapy**

**Publish your work in this journal**

*Breast Cancer - Targets and Therapy* is an international, peer-reviewed open access journal focusing on breast cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

**Submit your manuscript here:** https://www.dovepress.com/testimonials.php#